|Articles|July 25, 2022

Calyx and Qynapse Announce Partnership

Partnership to enable AI-enhanced medical imaging services for CNS clinical trials.

Calyx announced it has entered into a partnership with Qynapse. The partnership enables Calyx to adopt and deliver Qynapse's AI-powered neuroimaging analysis solutions, QyScore® and QyPredict® to its global pharmaceutical and biotech customers as they develop new medical treatments for central nervous system (CNS) disorders.

Read more about the partnership here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related Articles

ACT Brief Weekly Recap: How AI, eClinical Innovation, and Policy Shifts Are Reshaping Clinical Research
September 15th 2025
Phase IV Trial Shows Daybue Demonstrates Real-World Behavioral Improvements in Rett Syndrome
September 15th 2025
Capvaxive Demonstrates Robust Immune Responses in Children, Adolescents at Increased Risk of Pneumococcal Disease
September 15th 2025
NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
September 15th 2025
Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025
Trial Data Leads to NCCN Recommendation for Modeyso in Recurrent High Grade Glioma Patients
September 12th 2025

Trending on Applied Clinical Trials Online

Capvaxive Demonstrates Robust Immune Responses in Children, Adolescents at Increased Risk of Pneumococcal Disease

NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG

ACT Brief Weekly Recap: How AI, eClinical Innovation, and Policy Shifts Are Reshaping Clinical Research

Phase IV Trial Shows Daybue Demonstrates Real-World Behavioral Improvements in Rett Syndrome

© 2025 MJH Life Sciences^®

All rights reserved.